☆ 4.6 Article

Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)

Journal

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Volume 3, Issue 6, Pages -

Publisher

WILEY

DOI: 10.1161/JAHA.113.001330

Keywords

antiplatelet therapy; aspirin; clopidogrel; peripheral artery disease

Categories

Cardiac & Cardiovascular Systems

Funding

Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [290-2007-10066-I]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Cardiac & Cardiovascular Systems

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis

Di Liu, Wei Pan Xu, Hang Xu, Lin Zhao, Dao Qun Jin

Summary: Compared with aspirin, clopidogrel monotherapy in patients with coronary artery disease can reduce the risk of major adverse cardiac and cerebrovascular events, myocardial infarction, stroke, and major bleeding, with no significant difference in overall mortality and vascular death between the two groups.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

Rupert Bauersachs, Olivia Wu, Neil Hawkins, Kevin Bowrin, Piotr Wojciechowski, Emilie Clay, Maria Huelsebeck

Summary: This study compared the efficacy and safety of treatments used in patients with PAD undergoing peripheral revascularization. The results indicated that RIV plus ASA reduced the risk of revascularization compared to ASA monotherapy, but there was a trend towards increased major bleeding. Evidence for other comparators was insufficient to guide treatment decisions.

CARDIOVASCULAR THERAPEUTICS (2021)

Add to Collection

Review Medicine, General & Internal

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events

Leonardo De Luca, Elisa Bellettini, Dario Di Maio, Enrico Natale, Rita Lucia Putini, Sabrina Anticoli, Furio Colivicchi, Paolo Calabro, Francesco Musumeci, Domenico Gabrielli

Summary: Stroke is the leading cause of disability and mortality worldwide. Antiplatelet therapy plays a key role in managing stroke/TIA complications. Aspirin, clopidogrel, and ticagrelor are the most commonly discussed and used antiplatelet therapies.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Cell Biology

Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients

Valentine Robaux, Shakeel Kautbally, Audrey Ginion, Melanie Dechamps, Sibille Lejeune, Nassiba Menghoum, Luc Bertrand, Anne-Catherine Pouleur, Sandrine Horman, Christophe Beauloye

Summary: This study investigated the impact of antiplatelet treatments on tubulin acetylation, finding that dual antiplatelet therapy significantly increased levels of tubulin acetylation and reduced the proportion of patients with high levels of acetylation. These findings highlight the role of tubulin acetylation as a marker of platelet inhibition in response to dual antiplatelet therapy.

PLATELETS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease

Yujing Cheng, Yan Sun, Dai Zhang, Xiaoteng Ma, Chi Liu, Chengping Hu, Tienan Sun, Ziwei Zhao, Xiaoli Liu, Yujie Zhou

Summary: This study aimed to investigate the effects of smoking and CYP2C19 gene polymorphism on antiplatelet therapy. The results showed that ticagrelor plus aspirin reduced the recurrence risk of major adverse cardiovascular or cerebrovascular events (MACCE) in non-smokers, but not in smokers. There were no significant associations between antiplatelet medication and CYP2C19 gene polymorphism for the MACCE recurrence risk.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation

Jose Miguel Rivera-Caravaca, Anny Camelo-Castillo, Inmaculada Ramirez-Macias, Pablo Gil-Perez, Cecilia Lopez-Garcia, Maria Asuncion Esteve-Pastor, Esteban Orenes-Pinero, Antonio Tello-Montoliu, Francisco Marin

Summary: Peripheral artery disease (PAD) is often underestimated and undertreated, leading to dysregulated procoagulant, anticoagulant, and fibrinolytic pathways in patients. The combination of antiplatelets and anticoagulants has emerged as a potential alternative to antiplatelets alone, showing promising results in reducing cardiovascular outcomes without increasing bleeding risk.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery

Jianyu Qu, Heng Zhang, Chenfei Rao, Sipeng Chen, Yan Zhao, Hansong Sun, Yunhu Song, Sheng Liu, Liqing Wang, Wei Feng, Shuiyun Wang, Shengshou Hu, Zhe Zheng

Summary: Among patients undergoing coronary artery bypass grafting, dual antiplatelet therapy with clopidogrel plus aspirin is associated with a reduced risk of major adverse cardiovascular and cerebrovascular events within 6 months compared to aspirin monotherapy, without a significant increase in major bleeding.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Surgery

Use of Thromboelastography with Platelet Mapping to Identify Prothrombotic Coagulation Profiles in Patients with History of Cardiac Intervention Undergoing Lower Extremity Revascularization

Ryan Hall, Monica Majumdar, Ryan Cassidy, Zachary Feldman, Sasha Suarez, Guillaume Goudot, Tiffany Bellomo, Samuel Jessula, Amanda Kirshkaln, Anahita Dua

Summary: Patients with concomitant CAD and PAD undergoing lower extremity revascularization demonstrate prothrombotic abnormalities, less frequent use of dual antiplatelet therapy, and higher rates of full-dose anticoagulation. Decreased platelet inhibition is associated with postoperative MALE.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making

Graham R. McClure, Eric Kaplovitch, Noel Chan, Sonia S. Anand

Summary: Patients with peripheral artery disease (PAD) have a significant thrombotic risk, but often go unrecognized. Recent Canadian guidelines recommend dual pathway therapy initiation for stable PAD and postrevascularisation patients. However, there is ongoing discussion about identifying those PAD patients who would benefit most from these therapies while minimizing bleeding harm. Clinical equipoise also persists around questions such as the use of dual antiplatelet therapy in conjunction with rivaroxaban after high-risk endovascular interventions and the optimal therapy for patients experiencing acute limb ischemia. Dual pathway therapy with low-dose rivaroxaban and aspirin has emerged as the only regimen to reduce major adverse cardiovascular and limb events for patients with chronic PAD and high-risk comorbidities or limb features, or for patients after revascularisation. Urgently needed are randomized investigations to guide decision making for intensified antithrombotic therapy for patients at high risk.

CANADIAN JOURNAL OF CARDIOLOGY (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022

Vinai C. Bhagirath, David Nash, Darryl Wan, Sonia S. Anand

Summary: Peripheral artery disease (PAD) is associated with high risks of cardiovascular and limb events and death. Preventive therapies, such as antithrombotic therapy, lipid lowering, blood pressure control, diabetes management, smoking cessation, and exercise programs, have been shown to improve symptoms and reduce complications. However, these therapies are underutilised in PAD patients due to barriers including lack of knowledge and access to secondary prevention programs.

CANADIAN JOURNAL OF CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease

Ziwei Xi, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Yang Li, Jianfeng Zheng, Kefei Dou, Bo Xu, Yongjian Wu, Shubin Qiao, Weixian Yang, Yuejin Yang, Runlin Gao

Summary: This study demonstrates that in patients with SCAD undergoing complex PCI, ticagrelor can significantly reduce the risk of adverse cardiovascular events compared to clopidogrel, without an increased risk of major bleeding.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Hematology

Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease

Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Tobias Geisler, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo

Summary: This study compared the pharmacodynamic effects of dual-pathway inhibition (DPI) and standard dual antiplatelet therapy (DAPT) in patients with stable atherosclerotic disease. The results showed that DPI and DAPT did not differ in platelet-mediated global thrombogenicity, but DPI reduced thrombin generation. These observations support the efficacy and safety findings of DPI strategy observed in clinical trials.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of the Degree of Gastric Mucosal Injury between Patients Who Are Receiving Dual Antiplatelet Therapy or Single Antiplatelet Therapy

Yuji Shimada, Mariko Hojo, Yuji Kita, Yuji Ikeda, Sho Sato, Ayato Murata, Shunsuke Sato, Kohei Matsumoto, Yoichi Akazawa, Tsutomu Takeda, Kumiko Ueda, Hiroya Ueyama, Tomoyoshi Shibuya, Takuya Genda, Akihito Nagahara

Summary: This study compared the degree of gastric mucosal injury in patients taking low-dose aspirin in combination with clopidogrel with that of patients who were taking aspirin or clopidogrel alone. The results showed that the degree of gastric mucosal injury in patients receiving dual antiplatelet therapy (DAPT) was significantly higher than that in patients using clopidogrel alone and tended to be higher than that in patients using aspirin alone in real-world clinical practice.

DIAGNOSTICS (2022)

Add to Collection

Article Multidisciplinary Sciences

Antiplatelet treatment patterns and outcomes of secondary stroke prevention in the United States

Ellen O'Brien, Dejan Milentijevic, Rajarshi Roychowdhury, Smita Mitra, Cindy Y. Chen

Summary: This study evaluated outpatient antiplatelet treatment patterns and outcomes after first hospitalization for ischemic stroke or transient ischemic attack among adults without atrial fibrillation in the United States. The study found that many patients were not prescribed or discontinued antiplatelet therapy within 90 days of hospitalization, and in most cases, prescriptions were not compliant with secondary stroke prevention consensus guidelines. Therefore, more effective strategies for secondary stroke prevention are needed to improve outcomes in this patient population.

HELIYON (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis

Toshiki Kuno, Yujiro Yokoyama, Alexandros Briasoulis, Makoto Mori, Masao Iwagami, Tomo Ando, Hisato Takagi, Sripal Bangalore

Summary: This study compared the outcomes of single antiplatelet therapy versus 3- or 6-month DAPT following TAVR. Results showed that the risk of major bleeding was significantly higher in the 3- and 6-month DAPT groups compared to the single antiplatelet therapy group, with similar rates of stroke and all-cause mortality among the three groups.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes

Neda Rasouli, Irwin G. Brodsky, Ranee Chatterjee, Sun H. Kim, Richard E. Pratley, Myrlene A. Staten, Anastassios G. Pittas

Summary: Supplementation with vitamin D-3 for 24 months did not improve beta-cell function in people with prediabetes, but showed benefits in those with very low baseline vitamin D levels.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Letter Health Care Sciences & Services

Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial

Nathalie Moise, Karina W. Davidson, Gregory N. Clarke, Rowena J. Dolor, Karen L. Margolis, Ian M. Kronish

JOURNAL OF GENERAL INTERNAL MEDICINE (2022)

Add to Collection

Article Health Care Sciences & Services

Assessing Quality in Advance Care Planning Documentation: A Survey of Current Methods

Callie M. Berkowitz, Jessica Ma, Jared Lowe, Rowena J. Dolor

Summary: This study identified 8 quality domains for advance care planning (ACP) documentation through literature review, with each study assessing between 2 and 6 domains. Divergent methods, including manual qualitative analysis and natural language processing techniques, were utilized for assessing quality domains.

AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2022)

Add to Collection

Article Nutrition & Dietetics

Safety and tolerability of high-dose daily vitamin D3 supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes

Karen C. Johnson, Anastassios G. Pittas, Karen L. Margolis, Anne L. Peters, Lawrence S. Phillips, Ellen M. Vickery, Jason Nelson, Patricia R. Sheehan, David Reboussin, Saul Malozowski, Ranee Chatterjee

Summary: This study assessed the safety and tolerability of high-dose daily vitamin D3 supplementation. The results showed that in a high-risk population for diabetes who were appropriately monitored for safety, 4000 IU per day of vitamin D3 supplementation was safe and well tolerated, without increasing the risk of adverse events or serious adverse events.

EUROPEAN JOURNAL OF CLINICAL NUTRITION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial

Lili Zhang, Devvora Olalere, Thomas Mayrhofer, Daniel O. Bittner, Hamed Emami, Nina M. Meyersohn, Stefan B. Puchner, Aiden Abidov, Jamaluddin Moloo, Rowena J. Dolor, Daniel B. Mark, Maros Ferencik, Udo Hoffmann, Pamela S. Douglas, Michael T. Lu

Summary: This study compared the cardiovascular risk burden, coronary plaque, and major adverse events between Black and White individuals undergoing noninvasive testing, finding that Black individuals had a higher cardiovascular risk burden but lower rates of coronary artery calcium, stenosis, and high-risk plaque compared to White individuals.

JAMA CARDIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez

Summary: This study aimed to evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily for 10 days) compared with placebo for the treatment of mild to moderate COVID-19. The results showed that treatment with fluvoxamine did not improve the time to sustained recovery compared with placebo. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Nutrition & Dietetics

Effect of intratrial mean 25(OH)D concentration on diabetes risk, by race and weight: an ancillary analysis in the D2d study

Ranee Chatterjee, Clemontina A. Davenport, Ellen M. Vickery, Karen C. Johnson, Sangeeta R. Kashyap, Erin S. LeBlanc, Jason Nelson, Samuel Dagogo-Jack, Anastassios G. Pittas, Bess Dawson Hughes

Summary: Higher serum 25-hydroxyvitamin D is associated with lower type 2 diabetes risk. The effect of vitamin D on diabetes differs among people of color and those with overweight/obesity compared with individuals who are White or have normal weight.

AMERICAN JOURNAL OF CLINICAL NUTRITION (2023)

Add to Collection

Article Medicine, General & Internal

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization

Tracy Y. Wang, Abdus S. Wahed, Alison Morris, Lisa Baumann Kreuziger, John G. Quigley, Gervasio A. Lamas, Alexandra J. Weissman, Jose Lopez-Sendon, M. Margaret Knudson, Deborah M. Siegal, Raj S. Kasthuri, Andrew J. Alexander, Lana Wahid, Bassel Atassi, Peter J. Miller, Janice W. Lawson, Bela Patel, Jerry A. Krishnan, Nancy L. Shapiro, Deborah E. Martin, Andrei L. Kindzelski, Eric S. Leifer, Jungnam Joo, Lingyun Lyu, Annie Pennella, Brendan M. Everett, Mark W. Geraci, Kevin J. Anstrom, Thomas L. Ortel

Summary: This study aimed to determine whether anticoagulation is effective in reducing death and thromboembolic complications among patients discharged after COVID-19 hospitalization. The study was terminated early due to a lower-than-expected event rate and declining COVID-19 hospitalizations, leading to inconclusive results.

ANNALS OF INTERNAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Discriminative Accuracy of the CAPTURE Tool for Identifying Chronic Obstructive Pulmonary Disease in US Primary Care Settings

Fernando J. Martinez, MeiLan K. Han, Camden Lopez, Susan Murray, David Mannino, Stacey Anderson, Randall Brown, Rowena Dolor, Nancy Elder, Min Joo, Irfan Khan, Lyndee M. Knox, Catherine Meldrum, Elizabeth Peters, Cathie Spino, Hazel Tapp, Byron Thomashow, Linda Zittleman, Barry Make, Barbara P. Yawn

Summary: Chronic obstructive pulmonary disease (COPD) is often undiagnosed in primary care. The CAPTURE screening tool is effective in identifying US primary care patients with clinically significant, undiagnosed COPD.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Health Care Sciences & Services

Provider Interaction With an Electronic Health Record Notification to Identify Eligible Patients for a Cluster Randomized Trial of Advance Care Planning in Primary Care: Secondary Analysis

Jessica E. Ma, Jared Lowe, Callie Berkowitz, Azalea Kim, Ira Togo, R. Clayton Musser, Jonathan Fischer, Kevin Shah, Salam Ibrahim, Hayden B. Bosworth, Annette M. Totten, Rowena Dolor

Summary: This study aimed to describe the implementation and usage of an EHR notification for referring patients to an ACP study, evaluate the association of notifications with study referrals and engagement in ACP, and assess provider interactions with and perspectives on the notifications. It was found that an EHR notification can be effective in reminding providers to perform ACP conversations and refer patients to a clinical study, but excessive notifications may lead to alert fatigue and diminishing returns.

JOURNAL OF MEDICAL INTERNET RESEARCH (2023)

Add to Collection

Article Geriatrics & Gerontology

Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale

Jacob M. Joseph, Nicholas J. Pajewski, Rowena Dolor, Mary Ann H. Sellers, Letitia R. Perdue, Sheronda M. Peeples, Adam Henrie, Nancy Woolard, W. Schuyler P. Jones, Catherine R. Benziger, Ariela S. Orkaby, Amanda J. Mixon, Jeffrey D. VanWormer, Michael E. Shapiro, Christine S. Kistler, Tamar Polonsky, Ranee M. Chatterjee, Alanna E. Chamberlain, Daniel U. Forman, Kirk M. Knowlton, Thomas Gill, L. Kristin G. Newby, Bradley S. Hammill, Mine A. Cicek, Neely E. Williams, Jake Decker, Jiafu Ou, Jack Rubinstein, Gaurav Choudhary, Raul J. E. Gazmuri, Kenneth L. Schmader, Christianne P. Roumie, Camille B. Vaughan, Mark M. Effron, Rhonda A. Cooper-DeHoff, Mark C. Supiano, Raj C. Shah, Jeffrey F. Whittle, Adrian T. Hernandez, Walter D. Ambrosius, Jeff P. Williamson, Karen Alexander

Summary: This is a clinical trial that aims to investigate whether the initiation of statins can improve survival free of dementia and disability in adults aged 75 years and older. The trial will compare the effects of high-intensity statin therapy with placebo in a large population. The results will provide important insights into the impact of statins on the survival of older adults with dementia and disability.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

Add to Collection

Article Multidisciplinary Sciences

Primary care provider uptake of intensive behavioral therapy for obesity in Medicare patients, 2013-2019

Mounira Ozoor, Mark Gritz, Rowena J. Dolor, Jodi Summers Holtrop, Zhehui Luo

Summary: This cohort study analyzed the patterns of uptake of Intensive Behavioral Therapy (IBT) for obesity services among primary care providers (PCPs) serving the Medicare population in the U.S. Results showed that only a small percentage of PCPs continuously provided IBT services for Medicare patients with obesity, highlighting the need for further investigation and interventions.

PLOS ONE (2023)

Add to Collection

Correction Medicine, Research & Experimental

Integrating dissemination and implementation sciences within Clinical and Translational Science Award programs to advance translational research: Recommendations to national and local leaders (vol 5, e151, 2021)

Tara G. G. Mehta, Jane Mahoney, Aaron L. L. Leppin, Kathleen R. R. Stevens, Reza Yousefi-Nooraie, Brad H. H. Pollock, Rachel C. C. Shelton, Rowena Dolor, Harold Pincus, Sapana Patel, Justin B. Moore

JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Add to Collection

Article Anesthesiology

Opioid dose and pain effects of an online pain self-management program to augment usual care in adults with chronic pain: a multisite randomized clinical trial

Marian Wilson, Rowena J. Dolor, Daniel Lewis, Saundra L. Regan, Mary Beth Vonder Meulen, T. John Winhusen

Summary: Nonpharmacological interventions, such as online pain self-management programs, can effectively reduce opioid dose and manage pain for adults on long-term opioid therapy. These programs have significant benefits in reducing morphine equivalent dose and improving pain outcomes.

PAIN (2023)

Add to Collection

Article Medicine, Research & Experimental

Dissemination and implementation science resources, training, and scientific activities provided through CTSA programs nationally: Opportunities to advance D&I research and training capacity

Rachel C. Shelton, Rowena J. Dolor, Jonathan Tobin, Ana Baumann, Catherine Rohweder, Sapana Patel, Laura-Mae Baldwin

Summary: The Clinical and Translational Science Award (CTSA) Program hubs have the potential to advance dissemination and implementation (D&I) research and training capacity nationally. However, little is known about the support and services CTSA provides for D&I research. An environmental scan was conducted to address this gap, and it was found that challenges faced by CTSAs in developing and supporting D&I science activities include inadequate workforce and lack of understanding. Services provided by CTSAs include consultation programs, pilot funding, and workshops/seminars/conferences. Recommendations for the future include increasing training to meet demand and providing accessible tools/resources for D&I.

JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.